Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

BACKGROUND: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc ana...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Drugs Context
Hoofdauteurs: Pavelka, Karel, Szekanecz, Zoltán, Damjanov, Nemanja, Anić, Branimir, Tomšič, Matija, Mazurov, Vadim, Maksimovic, Marija, Nagy, Orsolya, Świerkot, Jerzy, Petranova, Tzvetanka, Veldi, Tiina, Baranauskaitė, Asta, Codreanu, Catalin, Andersone, Daina, Fleischmann, Roy
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioExcel Publishing Ltd 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574850/
https://ncbi.nlm.nih.gov/pubmed/33123205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-7-5
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items